BioPorto A/S (CPH:BIOPOR)
1.522
-0.008 (-0.52%)
May 8, 2025, 4:51 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Neutrophil Gelatinase-associated Lipocalin Tests | 18.56M |
Log In |
Log In |
Log In |
Log In |
Neutrophil Gelatinase-associated Lipocalin Tests Growth | 24.91% |
Log In |
Log In |
Log In |
Log In |
Antibodies | 10.68M |
Log In |
Log In |
Log In |
Log In |
Antibodies Growth | -11.24% |
Log In |
Log In |
Log In |
Log In |
Enzyme-linked Immunosorbent Assay Kits | 1.67M |
Log In |
Log In |
Log In |
Log In |
Enzyme-linked Immunosorbent Assay Kits Growth | -8.82% |
Log In |
Log In |
Log In |
Log In |
Royalty and Other | 45.00K |
Log In |
Log In |
Log In |
Log In |
Royalty and Other Growth | -81.48% |
Log In |
Log In |
Log In |
Log In |
Other Products and Licenses | - |
Log In |
Log In |
Log In |
Log In |
Other Products and Licenses Growth | - |
Log In |
Log In |
Log In |
Log In |
Other Neutrophil Gelatinase-associated Lipocalin | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
United States | 17.30M |
Log In |
Log In |
Log In |
Log In |
Europe | 9.71M |
Log In |
Log In |
Log In |
Log In |
Europe Growth | -3.82% |
Log In |
Log In |
Log In |
Log In |
Asia | 3.77M |
Log In |
Log In |
Log In |
Log In |
Asia Growth | -3.70% |
Log In |
Log In |
Log In |
Log In |
North America | 179.00K |
Log In |
Log In |
Log In |
Log In |
North America Growth | -98.80% |
Log In |
Log In |
Log In |
Log In |
Other Regions | - |
Log In |
Log In |
Log In |
Log In |
Other Regions Growth | - |
Log In |
Log In |
Log In |
Log In |